J&J to Invest Over $2 Billion in Biologics Manufacturing Facility, North Carolina
Johnson & Johnson has announced a significant investment exceeding $2 billion to establish a cutting-edge biologics manufacturing facility in Wilson, North Carolina, USA. This new facility aims to bolster the production of the company’s innovative biologics portfolio and pipeline, aligning with Johnson & Johnson’s strategic plan to advance over 70 novel therapy and product expansion filings and launches by the end of the decade. Construction is planned to begin in the first half of 2025.
Dapo Ajayi, Vice President of Innovative Medicine Supply Chain at Johnson & Johnson, emphasized the importance of a robust global supply chain.
Dapo Ajayi, Vice President, Innovative Medicine Supply Chain, Johnson & Johnson said:
“A strong, global supply chain is crucial, and we purposefully invest to ensure our transformational medicines reliably and efficiently reach patients around the world. We are investing in capacity and new technologies to enhance our industry leading capabilities and ensure a resilient supply chain for the future. North Carolina is an important hub for biopharmaceutical manufacturing and talent, and we are pleased to join this thriving life sciences ecosystem and become part of the Wilson community.”
The facility will focus on producing Johnson & Johnson’s biologic medicines in key areas such as oncology, immunology, and neuroscience, utilising the latest technology to enable efficient manufacturing operations. Once fully operational, the site is expected to employ approximately 420 full-time, highly skilled employees.
The new manufacturing facility is projected to boost the state’s economy by $2.3 billion over the 12-year period.
Image Credit: Johnson & Johnson
